Maravai LifeSciences Holdings Inc

MRVI

Equity

ISIN US56600D1072 / Valor 58353451

NASDAQ (2024-11-22)

USD 5.22+5.24%

Maravai LifeSciences Holdings Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Maravai LifeSciences Holdings Inc is a prominent player in the biopharmaceutical sector, providing critical support to biopharmaceutical companies and contract development and manufacturing organizations worldwide. Through its subsidiary, Cygnus Technologies, Maravai LifeSciences specializes in enhancing the biopharmaceutical development process by ensuring the purity and safety of a wide range of therapeutic products. These include antibodies, proteins, gene therapies, vaccines, and plasma derivatives. The company's expertise and services are integral to the successful development, manufacturing, and commercialization of these therapeutic solutions, addressing a crucial need in the biopharmaceutical industry for high-quality, reliable analytical tools and methodologies.

Summarized from source with an LLMView SourceSector: Technology

Revenue Decline

Maravai LifeSciences Holdings Inc. reported a revenue of $64.2 million for the first quarter of 2024, which represents a 19% decrease compared to the same period in the previous year. This decline was primarily driven by a 25% year-over-year decrease in Nucleic Acid Production revenue, attributed to lower demand for CleanCap analogs from COVID-19 vaccine manufacturers and the absence of large GMP services projects that were present in the prior year.

Net Loss

For the first quarter of 2024, Maravai LifeSciences Holdings Inc. reported a net loss of $(22.7) million. This is a significant increase in net loss compared to the $(1.3) million net loss reported in the first quarter of 2023. The increased net loss was influenced by various factors, including reduced revenue and increased operating expenses.

Adjusted EBITDA

Maravai LifeSciences Holdings Inc. reported an Adjusted EBITDA of $7.8 million for the first quarter of 2024, compared to $23.8 million in the same period of the previous year. The decrease in Adjusted EBITDA reflects the overall decline in revenue and the impact of increased costs associated with the company's operations and restructuring efforts.

Biologics Safety Testing Revenue

Despite the overall revenue decline, Maravai LifeSciences Holdings Inc. saw a 3% year-over-year increase in Biologics Safety Testing revenue, which amounted to $18.2 million for the first quarter of 2024. This growth indicates a steady demand for the company's biologics safety testing services, even as other segments experienced declines.

Financial Guidance for 2024

Maravai LifeSciences Holdings Inc. reaffirmed its financial guidance for the full year 2024, projecting revenue in the range of $265.0 million to $285.0 million. The company also expects Adjusted EBITDA margins to be between 23% and 25%. This guidance reflects the company's confidence in its long-term growth strategy and market opportunities, despite the challenges faced in the first quarter.

Summarized from source with an LLMView Source

Key figures

0.97%1Y

-86.1%3Y

%5Y

Performance

88.8%1Y

73.6%3Y

71.1%5Y

Volatility